Details of the Drug

General Information of Drug (ID: DMOTQ1I)

Drug Name
Ondansetron
Synonyms
DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Indication
Disease Entry ICD 11 Status REF
Chemotherapy-induced nausea MD90 Approved [1], [2]
Alcohol dependence 6C40.2 Phase 2 [1], [2]
Therapeutic Class
Antiemetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 293.4
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1887 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 572 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-4 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 9.3% [3]
Clearance
The clearance of drug is 0.38 L/h/kg [5]
Elimination
5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 4 hours (8 mg oral dose or intravenous dose) [6]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.16868 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.27% [8]
Vd
The volume of distribution (Vd) of drug is 160 L [9]
Water Solubility
The ability of drug to dissolve in water is measured as 5.7 mg/mL [4]
Chemical Identifiers
Formula
C18H19N3O
IUPAC Name
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Canonical SMILES
CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
InChI
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
InChIKey
FELGMEQIXOGIFQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4595
ChEBI ID
CHEBI:7773
CAS Number
99614-02-5
DrugBank ID
DB00904
TTD ID
D0K7WK
VARIDT ID
DR00909
INTEDE ID
DR1200
ACDINA ID
D00490

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3 receptor (5HT3R) TTNXLKE NOUNIPROTAC Agonist [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [15]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ondansetron
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Promethazine. Nausea/vomiting [MD90] [89]
Coadministration of a Drug Treating the Disease Different from Ondansetron (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Ondansetron and Methylene blue. Acquired methaemoglobinaemia [3A93] [89]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Ondansetron and Ivosidenib. Acute myeloid leukaemia [2A60] [90]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Midostaurin. Acute myeloid leukaemia [2A60] [89]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Idarubicin. Acute myeloid leukaemia [2A60] [89]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Arn-509. Acute myeloid leukaemia [2A60] [91]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Gilteritinib. Acute myeloid leukaemia [2A60] [92]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Ondansetron and Oliceridine. Acute pain [MG31] [89]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Rivastigmine. Alzheimer disease [8A20] [89]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Ondansetron and Metronidazole. Amoebiasis [1A36] [93]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Ondansetron and Ivabradine. Angina pectoris [BA40] [91]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Ondansetron and Bepridil. Angina pectoris [BA40] [89]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Ondansetron and Dronedarone. Angina pectoris [BA40] [89]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Ondansetron and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [94]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Cilostazol. Arterial occlusive disease [BD40] [89]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Posaconazole. Aspergillosis [1F20] [89]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Levalbuterol. Asthma [CA23] [95]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Pirbuterol. Asthma [CA23] [96]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Salbutamol. Asthma [CA23] [95]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Formoterol. Asthma [CA23] [96]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [91]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Ondansetron and Desipramine. Attention deficit hyperactivity disorder [6A05] [89]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Ofloxacin. Bacterial infection [1A00-1C4Z] [97]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Clarithromycin. Bacterial infection [1A00-1C4Z] [89]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Ondansetron and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [89]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Ondansetron and Sparfloxacin. Bacterial infection [1A00-1C4Z] [97]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Gemifloxacin. Bacterial infection [1A00-1C4Z] [97]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Norfloxacin. Bacterial infection [1A00-1C4Z] [97]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Levofloxacin. Bacterial infection [1A00-1C4Z] [97]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Lomefloxacin. Bacterial infection [1A00-1C4Z] [89]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Telithromycin. Bacterial infection [1A00-1C4Z] [89]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Retigabine. Behcet disease [4A62] [89]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Eribulin. Breast cancer [2C60-2C6Y] [89]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Lapatinib. Breast cancer [2C60-2C6Y] [89]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Bosutinib. Breast cancer [2C60-2C6Y] [91]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [98]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Olodaterol. Chronic obstructive pulmonary disease [CA22] [96]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Vilanterol. Chronic obstructive pulmonary disease [CA22] [95]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Salmeterol. Chronic obstructive pulmonary disease [CA22] [96]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Indacaterol. Chronic obstructive pulmonary disease [CA22] [96]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Arformoterol. Chronic obstructive pulmonary disease [CA22] [96]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Ondansetron and Dihydrocodeine. Chronic pain [MG30] [99]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Ondansetron and Levomilnacipran. Chronic pain [MG30] [89]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Isoproterenol. Conduction disorder [BC63] [95]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Halothane. Corneal disease [9A76-9A78] [89]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Sevoflurane. Corneal disease [9A76-9A78] [89]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Probucol. Coronary atherosclerosis [BA80] [89]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Ondansetron and Pasireotide. Cushing syndrome [5A70] [89]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Osilodrostat. Cushing syndrome [5A70] [91]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ondansetron caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [100]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Ondansetron and Sertraline. Depression [6A70-6A7Z] [89]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Ondansetron and Vilazodone. Depression [6A70-6A7Z] [89]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Ondansetron and Nefazodone. Depression [6A70-6A7Z] [89]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Ondansetron and Vortioxetine. Depression [6A70-6A7Z] [89]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Ondansetron and Isocarboxazid. Depression [6A70-6A7Z] [89]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Ondansetron and Milnacipran. Depression [6A70-6A7Z] [89]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Ondansetron and Escitalopram. Depression [6A70-6A7Z] [89]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Ondansetron and Desvenlafaxine. Depression [6A70-6A7Z] [89]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Ondansetron and Clomipramine. Depression [6A70-6A7Z] [89]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Ondansetron and Doxepin. Depression [6A70-6A7Z] [89]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Ondansetron and Maprotiline. Depression [6A70-6A7Z] [89]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Ondansetron and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [93]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [89]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Ondansetron and Deutetrabenazine. Dystonic disorder [8A02] [101]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Ondansetron and Ingrezza. Dystonic disorder [8A02] [102]
Cenobamate DMGOVHA Moderate Increased metabolism of Ondansetron caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [103]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ondansetron caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Rufinamide DMWE60C Moderate Increased metabolism of Ondansetron caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [91]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Solifenacin. Functional bladder disorder [GC50] [89]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Ketoconazole. Fungal infection [1F29-1F2F] [89]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Sunitinib. Gastrointestinal stromal tumour [2B5B] [89]
Rifampin DMA8J1G Moderate Increased metabolism of Ondansetron caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [104]
Rifapentine DMCHV4I Moderate Increased metabolism of Ondansetron caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [104]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Ondansetron and Procarbazine. Hodgkin lymphoma [2B30] [89]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [105]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [89]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [89]
Darunavir DMN3GCH Moderate Decreased metabolism of Ondansetron caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Ondansetron caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [93]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Polyethylene glycol. Irritable bowel syndrome [DD91] [91]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Phenolphthalein. Irritable bowel syndrome [DD91] [89]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Ondansetron caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [91]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Ondansetron and Crizotinib. Lung cancer [2C25] [107]
Brigatinib DM7W94S Moderate Increased metabolism of Ondansetron caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [108]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Ondansetron and Ceritinib. Lung cancer [2C25] [89]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Ondansetron and Osimertinib. Lung cancer [2C25] [109]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Ondansetron and Selpercatinib. Lung cancer [2C25] [91]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Ondansetron and Lumefantrine. Malaria [1F40-1F45] [93]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Ondansetron and Halofantrine. Malaria [1F40-1F45] [110]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Ondansetron and Hydroxychloroquine. Malaria [1F40-1F45] [111]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Primaquine. Malaria [1F40-1F45] [89]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [91]
Idelalisib DM602WT Moderate Decreased metabolism of Ondansetron caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [112]
IPI-145 DMWA24P Moderate Decreased metabolism of Ondansetron caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [113]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Ondansetron and Arsenic trioxide. Mature B-cell lymphoma [2A85] [114]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Ondansetron and Vemurafenib. Melanoma [2C30] [89]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and LGX818. Melanoma [2C30] [115]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Ondansetron caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [91]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Ondansetron and Almogran. Migraine [8A80] [89]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Ondansetron and Frovatriptan. Migraine [8A80] [89]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Ondansetron and Rizatriptan. Migraine [8A80] [89]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Ondansetron and Naratriptan. Migraine [8A80] [89]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Ondansetron and Lasmiditan. Migraine [8A80] [89]
Exjade DMHPRWG Moderate Decreased metabolism of Ondansetron caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [116]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Ondansetron and Panobinostat. Multiple myeloma [2A83] [117]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Ondansetron and Thalidomide. Multiple myeloma [2A83] [93]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Ondansetron and Siponimod. Multiple sclerosis [8A40] [93]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Ondansetron and Fingolimod. Multiple sclerosis [8A40] [89]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Ondansetron and Ozanimod. Multiple sclerosis [8A40] [118]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Romidepsin. Mycosis fungoides [2B01] [89]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Ondansetron and Nilotinib. Myeloproliferative neoplasm [2A20] [89]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Dasatinib. Myeloproliferative neoplasm [2A20] [119]
Bupropion DM5PCS7 Major Additive serotonergic effects by the combination of Ondansetron and Bupropion. Nicotine use disorder [6C4A] [89]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Entrectinib. Non-small cell lung cancer [2C25] [93]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Ondansetron and Sibutramine. Obesity [5B80-5B81] [89]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Ondansetron and Dexfenfluramine. Obesity [5B80-5B81] [89]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Ondansetron and Levomethadyl Acetate. Opioid use disorder [6C43] [91]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Ondansetron and Lofexidine. Opioid use disorder [6C43] [89]
Olaparib DM8QB1D Moderate Increased metabolism of Ondansetron caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [93]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Rucaparib. Ovarian cancer [2C73] [89]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Ondansetron and Oxymorphone. Pain [MG30-MG3Z] [99]
Dezocine DMJDB0Y Moderate Additive serotonergic effects by the combination of Ondansetron and Dezocine. Pain [MG30-MG3Z] [99]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Buprenorphine. Pain [MG30-MG3Z] [89]
Hydrocodone DMQ2JO5 Moderate Additive serotonergic effects by the combination of Ondansetron and Hydrocodone. Pain [MG30-MG3Z] [99]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Triclabendazole. Parasitic worm infestation [1F90] [89]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Pimavanserin. Parkinsonism [8A00] [120]
Abametapir DM2RX0I Moderate Decreased metabolism of Ondansetron caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [121]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Famotidine. Peptic ulcer [DA61] [93]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Ondansetron and Macimorelin. Pituitary gland disorder [5A60-5A61] [122]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Ondansetron and Lefamulin. Pneumonia [CA40] [123]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Ondansetron caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [124]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Degarelix. Prostate cancer [2C82] [91]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Ondansetron and ABIRATERONE. Prostate cancer [2C82] [91]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Enzalutamide. Prostate cancer [2C82] [91]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Relugolix. Prostate cancer [2C82] [91]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Bicalutamide. Prostate cancer [2C82] [91]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Levomepromazine. Psychotic disorder [6A20-6A25] [89]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Ondansetron and Gatifloxacin. Respiratory infection [CA07-CA4Z] [125]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Quetiapine. Schizophrenia [6A20] [89]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Ondansetron and Mesoridazine. Schizophrenia [6A20] [89]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Aripiprazole. Schizophrenia [6A20] [93]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Ondansetron and Iloperidone. Schizophrenia [6A20] [89]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Paliperidone. Schizophrenia [6A20] [89]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Ondansetron and Amisulpride. Schizophrenia [6A20] [126]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Asenapine. Schizophrenia [6A20] [89]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Ondansetron and Pimozide. Schizophrenia [6A20] [91]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ondansetron caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [91]
Larotrectinib DM26CQR Moderate Decreased metabolism of Ondansetron caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [93]
Armodafinil DMGB035 Minor Increased metabolism of Ondansetron caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [127]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Ondansetron and LEE011. Solid tumour/cancer [2A00-2F9Z] [89]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Ondansetron and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [89]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [91]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [89]
Pitolisant DM8RFNJ Moderate Increased metabolism of Ondansetron caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [91]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [89]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Ondansetron caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [128]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Lenvatinib. Thyroid cancer [2D10] [89]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Ondansetron and Cabozantinib. Thyroid cancer [2D10] [91]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Ondansetron and Papaverine. Tonus and reflex abnormality [MB47] [129]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [130]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Ondansetron and Procainamide. Ventricular tachyarrhythmia [BC71] [89]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Propafenone. Ventricular tachyarrhythmia [BC71] [89]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Ondansetron and Flecainide. Ventricular tachyarrhythmia [BC71] [89]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Ondansetron and Amiodarone. Ventricular tachyarrhythmia [BC71] [89]
⏷ Show the Full List of 163 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aspartame E00402 134601 Flavoring agent
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben E00543 23663626 Antimicrobial preservative
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ondansetron 4 mg tablet 4 mg Disintegrating Oral Tablet Oral
Ondansetron 8 mg tablet 8 mg Disintegrating Oral Tablet Oral
Ondansetron Hydrochloride eq 8mg base tablet eq 8mg base Tablet Oral
Ondansetron Hydrochloride eq 4mg base tablet eq 4mg base Tablet Oral
Ondansetron 4 mg tablet 4 mg Oral Tablet Oral
Ondansetron 8 mg tablet 8 mg Oral Tablet Oral
Ondansetron 24 mg tablet 24 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2290).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Health Canada Approved Drug Products: Sunvepra (asunaprevir) capsule
4 BDDCS applied to over 900 drugs
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Roila F, Del Favero A: Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995 Aug;29(2):95-109. doi: 10.2165/00003088-199529020-00004.
10 Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
11 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
12 The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999 Apr;65(4):377-81.
13 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
14 Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2006 Sep;29(9):1931-5.
17 Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
28 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
29 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
30 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
31 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
32 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
33 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
34 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
35 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
36 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
37 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
38 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
39 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
40 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
41 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
42 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
43 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
44 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
45 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
46 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
47 Drug Interactions Flockhart Table
48 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
49 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
50 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
51 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
52 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
53 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
54 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
55 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
56 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
57 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
58 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
59 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
60 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
61 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
62 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
63 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
64 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
65 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
66 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
67 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
68 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
69 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
70 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
71 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
72 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
73 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
74 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
75 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
76 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
77 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
78 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
79 New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
80 Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
81 The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
82 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
83 Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
84 Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
85 Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
86 Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
87 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
88 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
89 Canadian Pharmacists Association.
90 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
91 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
92 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
93 Cerner Multum, Inc. "Australian Product Information.".
94 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
95 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
96 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
97 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
98 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
99 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
100 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
101 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
102 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
103 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
104 Villikka K, Kivisto KT, Neuvonen PJ "The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron." Clin Pharmacol Ther 65 (1999): 377-81. [PMID: 10223773]
105 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
106 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
107 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
108 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
109 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
110 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
111 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
112 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
113 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
114 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
115 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
116 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
117 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
118 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
119 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
120 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
121 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
122 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
123 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
124 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
125 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
126 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
127 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
128 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
129 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
130 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]